SpectronRx Europe SRL
SpectronRx Europe reported total assets of 198,933 € at the end of the 2025 financial year (annual accounts filed with the NBB on 29 May 2026).
The score of SpectronRx Europe shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
The full file covers 2 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
SpectronRx Europe's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 29 May 2026
- Year ended 31 Dec 2024filed on 05 Aug 2025
SpectronRx Europe's financial analysis
- Solvency-59.0%sector median: 56.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of SpectronRx Europe
SpectronRx Europe's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1006.683.123
- VAT number
- BE1006683123
- Peppol
- Registered · 0208:1006683123 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 01 Mar 2024
- Registered office
- 1850 Grimbergen
- Latest accounts
- 2025 · filed on 29 May 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
SpectronRx Europe (SRL) has been based in Grimbergen since 2024, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net loss of 97,901 € and equity of −117,302 €; its revenue is not published.
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to SpectronRx Europe
Companies in the same business, of comparable size and area, outside its group.
- GRNR Invest Manufacture of basic pharmaceutical products Zemst · balance sheet €2.26m
- Novozymatic Manufacture of basic pharmaceutical products Kapellen · balance sheet 148,440 €
- Harika Lifij Manufacture of basic pharmaceutical products Evere · balance sheet 105,370 €
- Brupharm Pharmalab Manufacture of pharmaceutical preparations Mons · balance sheet 298,430 €
- NO Headache Manufacture of basic pharmaceutical products Uccle · balance sheet 261,728 €
- Medipharm Worldwide Group Manufacture of basic pharmaceutical products Tienen · balance sheet 331,081 €
- Evarmed Manufacture of basic pharmaceutical products Diepenbeek · balance sheet 51,346 €
- Apotheek de Lieve Retail sale of pharmaceutical products Lievegem · balance sheet 418,337 €
Frequently asked questions about SpectronRx Europe
What is the revenue of SpectronRx Europe?
SpectronRx Europe files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of SpectronRx Europe?
In Belgium, the VAT number is the company number prefixed with BE: BE1006683123 for SpectronRx Europe, if the company is VAT-registered. Its company number (CBE) is 1006.683.123.
Where is the registered office of SpectronRx Europe?
According to the CBE register, the registered office of SpectronRx Europe is in 1850 Grimbergen.
What is the equity of SpectronRx Europe?
At the close of the 2025 financial year, the equity of SpectronRx Europe amounts to -117,302 €, a solvency of -59.0% of total assets.
Who manages SpectronRx Europe?
The register lists 5 active mandates at SpectronRx Europe. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of SpectronRx Europe
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →